Evaluation of Pancreatic β-cell Differentiation Efficiency of Human iPSC Lines for Clinical Use.

Current stem cell research & therapy Pub Date : 2024-01-05 DOI:10.2174/011574888X267226231126185532

Ayumi Horikawa, Kyoko Tsuda, Takayoshi Yamamoto, Tatsuo Michiue

{"title":"Evaluation of Pancreatic β-cell Differentiation Efficiency of Human iPSC Lines for Clinical Use.","authors":"Ayumi Horikawa, Kyoko Tsuda, Takayoshi Yamamoto, Tatsuo Michiue","doi":"10.2174/011574888X267226231126185532","DOIUrl":null,"url":null,"abstract":"Background: Transplantation of pancreatic β-cells generated from human induced pluripotent stem cells (hiPSCs) has great potential as a root treatment for type 1 diabetes. However, their current level of efficiency to differentiate into β-cells is still not at par for clinical use. Previous research has shown that differentiation efficiency varies among human embryonic stem cells and mouse-induced pluripotent stem cell lines. Therefore, selecting a suitable cell line for efficient induction into desired tissues and organs is crucial.Method: In this study, we have evaluated the efficiency of 15 hiPSC lines available for clinical use to differentiate into pancreatic β-cells.Results: Our investigation has revealed induction efficiency to differ among the hiPSC lines, even when derived from the same donor. Among the hiPSC lines tested, the 16A01 cell line exhibited the highest insulin expression and low glucagon expression, suggesting that this cell line is suitable for differentiation into β-cells.Conclusion: Our study has demonstrated the importance of selecting a suitable hiPSC line for effective differentiation into β-cells.","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current stem cell research & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011574888X267226231126185532","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Transplantation of pancreatic β-cells generated from human induced pluripotent stem cells (hiPSCs) has great potential as a root treatment for type 1 diabetes. However, their current level of efficiency to differentiate into β-cells is still not at par for clinical use. Previous research has shown that differentiation efficiency varies among human embryonic stem cells and mouse-induced pluripotent stem cell lines. Therefore, selecting a suitable cell line for efficient induction into desired tissues and organs is crucial.

Method: In this study, we have evaluated the efficiency of 15 hiPSC lines available for clinical use to differentiate into pancreatic β-cells.

Results: Our investigation has revealed induction efficiency to differ among the hiPSC lines, even when derived from the same donor. Among the hiPSC lines tested, the 16A01 cell line exhibited the highest insulin expression and low glucagon expression, suggesting that this cell line is suitable for differentiation into β-cells.

Conclusion: Our study has demonstrated the importance of selecting a suitable hiPSC line for effective differentiation into β-cells.

查看原文本刊更多论文

评估用于临床的人类 iPSC 株系的胰腺 β 细胞分化效率

背景：移植由人类诱导多能干细胞（hiPSCs）产生的胰腺β细胞作为治疗1型糖尿病的根本方法具有巨大潜力。然而，目前它们分化成 β 细胞的效率仍未达到临床应用的水平。以往的研究表明，人类胚胎干细胞和小鼠诱导多能干细胞系的分化效率各不相同。因此，选择合适的细胞系以高效诱导成所需组织和器官至关重要：在这项研究中，我们评估了 15 个临床使用的 hiPSC 株系分化成胰腺 β 细胞的效率：结果：我们的调查显示，即使来自同一供体，不同 hiPSC 品系的诱导效率也不尽相同。在测试的 hiPSC 细胞系中，16A01 细胞系的胰岛素表达量最高，而胰高血糖素表达量较低，这表明该细胞系适合分化成 β 细胞：我们的研究表明，选择合适的 hiPSC 株系对有效分化成 β 细胞非常重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current stem cell research & therapy

自引率

0.00%

发文量

文献相关原料

公司名称	产品信息	采购帮参考价格